Chemotherapy: Open Access

Chemotherapy: Open Access
Open Access

ISSN: 2167-7700

Editor Note - (2016) Volume 5, Issue 4

View PDF Download PDF

Chemotherapy a Last Resort for Cancer Treatment

Alireza Heidari*
Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA, USA
*Corresponding Author: Alireza Heidari, Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA, USA Email:

Abstract

Chemotherapy deals with various types of therapeutic techniques such as antimicrobial chemotherapies, gynecological cancers, squamous cell carcinoma, tumorigenesis, chemo resistance, radiotherapy, electro chemotherapy used to treat several dreadful diseases. Imatinib and Nilotinib resistant gene identified in the chronic myeloid leukemia patient. Authors H Cheng et al. found a new mutation N796S in the BCR (exon 10) domain with T315I and F359V mutations, it was evaluated by the next generation exon sequencing technique. The change imposed by mutations was evaluated by measurement of hematologic, cytogenetic and molecular responses. Many studies exerted to explore the function of this new mutation N796S, is unknown and hence study suggests further to be explored in TKIs resistance [1].

Editor’s Note

Chemotherapy deals with various types of therapeutic techniques such as antimicrobial chemotherapies, gynecological cancers, squamous cell carcinoma, tumorigenesis, chemo resistance, radiotherapy, electro chemotherapy used to treat several dreadful diseases.

Imatinib and Nilotinib resistant gene identified in the chronic myeloid leukemia patient. Authors Cheng et al. found a new mutation N796S in the BCR (exon 10) domain with T315I and F359V mutations, it was evaluated by the next generation exon sequencing technique. The change imposed by mutations was evaluated by measurement of hematologic, cytogenetic and molecular responses. Many studies exerted to explore the function of this new mutation N796S, is unknown and hence study suggests further to be explored in TKIs resistance [1].

This study triedto analyze prognostic role of micro–vascular density and mucin production, wherein examines certain clinical and pathological factors may impact on the patient survival in lung adenocarcinoma of Pakistan. The present study noted few reasons poor survival in patients with primary pulmonary adenocarcinoma. Future studies can be focused to determine the role of mentioned factors in prognostication of treatment plan in anew diagnosed individuals [2].

Zhu et al. exerted to investigate the in vitro effect of alpha fetoprotein (AFP) on benzyl–isothiocyanate (BITC) arresting cell cycle in human liver cancer cells line. Further insight on the possible role and mechanism of BITC inhibited proliferation of Hepato Cellular Carcinoma (HCC) cells. His findings suggest that the BITC could down regulate the expression of cyclin B1, CDK1, Cdc25c and up regulate the expression of Weel, hence it inhibits the growth of HCC cells and induce to arrest cell cycle G2/M phase [3].

Mini review presented by Dong et al., had discussed on targeting ROS for cancer therapy. ROS merely swayed by the endogenous or exogenous cellular activity, leading to DNA/RNA damage, oxidative stress and abnormal cell signaling. This review article speaks about the factors which imbalance the cellular homeostasis or redox balance or which induce tumorigenesis [4].

References

  1. Cheng H, Huang C, Qiu H, Zhang W, Chen L, et al. (2016) A New Mutation Identified in an Imatinib and Nilotinib Resistant Chronic Myeloid Leukemia Patient. Chemo Open Access 5:193.
  2. Ullah E, Nagi AH, Ashraf M, Pasha AK, Maher KR, et al. (2016) Prognostic Role of Microvascular Density and Mucin Production in 56 Cases of Adenocarcinoma of Lung- An Experience from a Center in Lahore, Pakistan. Chemo Open Access 5:194.
  3. Zhu M, Li W, Dong X , Zhou P, Guo J, et al. (2016) Alpha Fetoprotein Plays Antagonistic Role in Benzyl-Isothiocyanate Arresting Cell Cycle in Liver Cancer Cells. Chemo Open Access 5: 195.
  4. Dong J, Liu, Zhu R (2016) Targeting ROS for Cancer Therapy. Chemo Open Access 5: 199.
Citation: Heidari A (2016) Chemotherapy a Last Resort for Cancer Treatment. Chemo Open Access 5:e130.

Copyright: © 2016 Heidari A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Top